Anti-Human FAS (CD95) (CPTC-FAS-1) – Purified No Carrier Protein

Synthetic Peptide EA (pY) DTLIK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0111P-3F2-H2/K4 activity is directed against human Fas peptide sequence EAYDTLIK.

CPTC-Fas-1

Fas (also known as TNFRSF6, CD95) is a member of the tumor necrosis factor (TNF) superfamily that induces apoptosis through activation of caspases¹. When bound to its cognate cytokine ligand (FasL), Fas triggers apoptosis or other forms of cell death via a six alpha helical fold called a death domain. During this process, Fas recruits FADD, a receptor protein that mediates recruitment of caspase-8, which then activates apoptosis via cleavage of downstream substrates.

Fas is also involved in the immune system¹. Fas can potentiate a response to pathogens by activating NF-κB and promoting IL-1β production. Additionally, Fas co-stimulation during T cell activation can co-stimulate T cell proliferation and differentiation into short-lived effector memory T cells. Defects in Fas signaling can lead to autoimmunity (underexpression) or cancer (overexpression). Fas blockade is being investigated for the treatment of cancer.

EB0111P-3F2-H2/K4 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from residues 289- 296 of human Fas that is phosphorylated at position Y291, EA(pY)DTLIK². EB0111P-3F2-H2/K4 does not detect Fas by immunohistochemistry, reverse phase protein array, or Western blotting³.

Fas is expressed on cell surfaces, can be found in lipid rafts, and some isoforms can be secreted.

TNFSF6/FASLG, FADD, CASP8, NOL3, DAXX, RIPK1, FAIM2, BABAM2, FEM1B, CALM

1 Yi F, Frazzette N, Cruz AC, et al. Trends Mol Med. 24(7):642-653. 2018.
2 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
3 https://antibodies.cancer.gov/detail/CPTC-FAS-1